Danish biotech startup Bactolife has secured over €30 million in a Series B round led by CBIV and EIFO, with support from Novo Holdings and ATHOS. The funding will advance human clinical studies, scale production, and support US market entry for its protein-based, non-antibiotic gut health solutions.